STOCK TITAN

ADC Therapeutics SA (ADCT) Financials

ADCT NYSE
Trailing 12 months to September 30, 2026
Revenue $84.9M +12.8% YoY
Net Income -$81.2M n/m YoY
EPS (Diluted) -$1.12 FY2025 annual
Free Cash Flow -$100.5M n/m YoY
Market Cap $180.0M as of Nov 20, 2026
Price / Sales 2.1x on $84.9M revenue, trailing 12 months to September 30, 2026
Price / Earnings n/m net loss, so no earnings multiple, trailing 12 months to September 30, 2026
Price / Book n/m negative shareholder equity, so no book multiple, Q3 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 20, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q3 FY2026, ended Sep 30, 2026 Reported Currency USD FYE December

Newest figures come from the 10-Q for Q3 FY2026, filed Nov 9, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the ADCT SEC filings page.

ADC Therapeutics SA (ADCT) reported $84.9M in revenue over the twelve months to Sep 30, 2026, up 12.8% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 4 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI ADCT FY2025

Revenue is recovering, but ADC Therapeutics still funds a development-stage cost base externally while liabilities exceed assets.

Revenue rose 14.9% from FY2024 to FY2025 while operating margin improved by 35.1 percentage points; nevertheless, operating cash outflow increased from $123.8M to $141.2M. That divergence means the margin recovery has not yet translated into cash generation, so reported earnings improvement alone overstates the operating progress.

R&D was $104.0M against $81.4M of FY2025 revenue, so the company remains economically development-stage: product investment alone exceeded sales before SG&A and other costs. Even after SG&A fell 7.0%, operating loss remained $121.5M, indicating cost reductions narrowed the gap without reaching break-even.

Liabilities equaled 157.5% of assets in FY2025, leaving equity negative at $185.8M. Financing cash flow was $150.9M against $141.2M of operating cash outflow, showing reliance on external funding; that separates short-term liquidity from long-term solvency.

[ NOT FINANCIAL ADVICE ]

Financial Health Signals

Cash Runway Dilution R&DIntensity Revenue Progress BurnTrend BalanceSheet 50 / 100
Financial Health Score 50/100
Scored as: Emerging companies peer group

Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group, and the overall is the average of the dimensions that can be computed. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of ADC Therapeutics SA's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Cash Runway
50

ADC Therapeutics SA held $261.3M in cash, cash equivalents and investments at the end of fiscal year 2025, and its operations used $141.2M of cash that year. Cash Runway ranks emerging companies on the size of that balance against the outflow behind it, and ADC Therapeutics SA scores 50/100 among other emerging companies.

Dilution
35

Dilution ranks emerging companies on the yearly rate at which their shares outstanding grew across the last three fiscal years (the last two where the earliest reports none), a slower rise ranking higher because each round of funding spreads the same business across more owners. ADC Therapeutics SA scores 35/100 on it among other emerging companies.

R&D Intensity
77

ADC Therapeutics SA spent $104.0M on research and development in fiscal year 2025, which was 51.3% of its operating costs that year. R&D Intensity ranks emerging companies on the share of operating costs that goes into research, and ADC Therapeutics SA scores 77/100 among other emerging companies.

Revenue Progress
51

Revenue Progress ranks emerging companies on the yearly rate at which their revenue compounded across the last three fiscal years (the last two where the earliest reports none), counted in the currency each company reports in. ADC Therapeutics SA scores 51/100 on it among other emerging companies.

Burn Trend
40

Burn Trend ranks emerging companies on how far their operating cash flow moved between the newest fiscal year and the one two years earlier, measured against the cash the earlier year used, and a move toward generating cash ranks higher. ADC Therapeutics SA scores 40/100 on it among other emerging companies.

Balance Sheet
44

ADC Therapeutics SA's cash, cash equivalents and investments came to $261.3M at the end of fiscal year 2025, against $509.0M of total liabilities. Balance Sheet ranks emerging companies on that comparison, and ADC Therapeutics SA scores 44/100 among other emerging companies.

Altman Z-Score Distress
-6.99

ADC Therapeutics SA scores -6.99, below the 1.81 distress threshold. The score is pulled down most by an accumulated deficit of $1.6B against total assets of $323.1M. This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial
5/8

ADC Therapeutics SA passes 5 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality No Cash Backing
N/A

ADC Therapeutics SA reported a net loss of $142.6M while operations used $141.2M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Interest Coverage At Risk
N/A

ADC Therapeutics SA reported an operating loss of $121.5M against $16.3M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue
$21.7M
YoY+32.2%
QoQ+12.8%

ADC Therapeutics SA generated $21.7M in revenue in Q3 2026. This represents an increase of 32.2% from the same quarter a year earlier. Against the prior quarter it is up 12.8%.

Net Income
-$25.3M
YoYn/m
QoQn/m

ADC Therapeutics SA reported a net loss of $25.3M in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

EPS (Diluted)
-$0.16
YoYn/m
QoQn/m

ADC Therapeutics SA earned -$0.16 per diluted share (EPS) in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

EBITDA

Not reported for Q3 2026.

Cash & Balance Sheet

Free Cash Flow
-$27.9M
YoYn/m
QoQn/m

ADC Therapeutics SA recorded an outflow of $27.9M in free cash flow in Q3 2026, representing a cash shortfall after capex. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Cash & Debt
$189.2M
YoY-19.4%
QoQ-13.6%

ADC Therapeutics SA held $189.2M in cash as of Q3 2026; no long-term debt figure is on record for that period.

Shares Outstanding
128M
YoY+3.1%
QoQ+0.1%

ADC Therapeutics SA had 128M shares outstanding in Q3 2026. This represents an increase of 3.1% from the same quarter a year earlier. Against the prior quarter it is up 0.1%.

Dividends Per Share

Not reported for Q3 2026.

Margins & Returns

Operating Margin
-66.1%

ADC Therapeutics SA's operating margin was -66.1% in Q3 2026, reflecting core business profitability. No change is given against Q3 2025: its reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Gross Margin

Not reported for Q3 2026.

Net Margin

Not shown for Q3 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Return on Equity

Not reported for Q3 2026.

Capital Allocation

R&D Spending
$14.7M
YoY-45.0%
QoQ-15.1%

ADC Therapeutics SA invested $14.7M in research and development in Q3 2026. This represents a decrease of 45.0% from the same quarter a year earlier. Against the prior quarter it is down 15.1%.

Capital Expenditures
$0
YoYn/m
QoQn/m

ADC Therapeutics SA reported no capital expenditure in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Share Buybacks

Not reported for Q3 2026.

ADCT Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

ADCT quarterly income statement
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Revenue$21.7M+32.2%$19.2M+2.2%$20.9M-9.5%$23.1M+36.4%$16.4M-11.0%$18.8M+8.2%$23.0M+27.6%$16.9M+0.7%
R&D Expenses$14.7M-45.0%$17.4M-42.3%$19.9M-31.3%$18.2M-32.9%$26.8M-17.5%$30.1M+23.9%$28.9M+12.4%$27.1M-10.6%
SG&A Expenses$19.4M+2.1%$22.3M+17.4%$22.6M+10.2%$21.4M+2.7%$19.0M-8.0%$19.0M-9.4%$20.5M-12.4%$20.9M-17.2%
Operating Income-$14.3Mn/m-$25.4Mn/m-$25.2Mn/m-$17.9Mn/m-$31.0Mn/m-$44.1Mn/m-$28.5Mn/m-$32.4Mn/m
EBITDAN/AN/AN/A-$17.9Mn/m-$31.0Mn/m-$43.8Mn/m-$28.1Mn/m-$32.1Mn/m
Interest Expense$13.7M+2.5%$13.5M+3.9%$12.3M+1.0%-$22.3Mn/m$13.4M+2.1%$13.0M+2.5%$12.2M-2.1%-$21.7Mn/m
Income Tax$0n/m$0-100.0%$0-100.0%-$404Kn/m$0-100.0%$1.3M+435.9%$165K+1.2%-$321K-100.7%
Net Income-$25.3Mn/m-$16.6Mn/m-$33.0Mn/m-$6.4Mn/m-$41.0Mn/m-$56.6Mn/m-$38.6Mn/m-$30.7Mn/m
EPS (Basic)-$0.16n/m-$0.11n/m-$0.21n/mN/A-$0.30n/m-$0.50n/m-$0.36n/m-$0.27n/m
EPS (Diluted)-$0.16n/m-$0.11n/m-$0.21n/mN/A-$0.30n/m-$0.50n/m-$0.36n/m-$0.27n/m
Diluted Shares (Avg)155M+13.9%155M+36.3%154M+43.8%N/A136M+30.2%114M+18.9%107M+29.9%N/A

Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit.

ADCT Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

ADCT quarterly balance sheet
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Total Assets$255.9M-11.7%$279.4M-13.1%$291.5M+7.0%$323.1M+0.4%$289.8M-17.0%$321.6M-13.5%$272.5M-11.5%$322.0M-9.2%
Current Assets$238.6M-16.9%$261.7M-17.9%$276.8M+7.3%$306.3M+5.2%$287.1M-13.8%$318.8M-10.3%$258.0M-11.1%$291.3M-13.4%
Cash & Equivalents$189.2M-19.4%$219.1M-17.2%$231.0M+18.6%$261.3M+4.2%$234.7M-14.4%$264.6M-11.8%$194.7M-16.9%$250.9M-10.0%
Short-Term Investments$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m
Inventory$5.6M-68.8%$4.9M-72.2%$4.8M-72.6%$4.2M+85.9%$18.0M+12.3%$17.8M+16.9%$17.4M+9.1%$2.3M-86.1%
Long-Term Investments$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m
Total Liabilities$505.0M-4.3%$507.6M-2.5%$507.9M-0.6%$509.0M-3.0%$527.9M+1.3%$520.7M+3.4%$510.8M+1.7%$524.6M+4.3%
Current Liabilities$78.1M+25.9%$86.3M+33.6%$67.6M+17.0%$70.2M-12.8%$62.0M-8.3%$64.6M+12.1%$57.8M-8.2%$80.5M+18.9%
Non-Current Liabilities$426.9M-8.4%$421.3M-7.6%$440.2M-2.8%$438.8M-1.2%$465.9M+2.8%$456.1M+2.3%$453.0M+3.1%$444.2M+2.0%
Total Equity-$249.2Mn/m-$228.2Mn/m-$216.4Mn/m-$185.8Mn/m-$238.2Mn/m-$199.2Mn/m-$238.2Mn/m-$202.6Mn/m
Retained Earnings-$1.7Bn/m-$1.7Bn/m-$1.7Bn/m-$1.6Bn/m-$1.6Bn/m-$1.6Bn/m-$1.5Bn/m-$1.5Bn/m

Not reported in any period shown, so not listed: Accounts Receivable, Goodwill, Long-Term Debt.

ADCT Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

ADCT quarterly cash flow statement
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Operating Cash Flow-$27.9Mn/m-$11.8Mn/m-$29.7Mn/m-$31.1Mn/m-$29.6Mn/m-$24.1Mn/m-$56.3Mn/m-$21.9Mn/m
Depreciation & AmortizationN/AN/AN/A$0-100.0%$0-100.0%$362K+11.0%$342K+3.3%$341K+1.8%
Stock-Based CompensationN/AN/A$2.4M+0.9%N/AN/AN/A$2.4M+1432.3%N/A
Capital Expenditures$0n/m$0n/m$32K-87.9%$0-100.0%$0-100.0%$0-100.0%$264K-50.3%$90K-72.5%
Free Cash Flow-$27.9Mn/m-$11.8Mn/m-$29.7Mn/m-$31.1Mn/m-$29.6Mn/m-$24.1Mn/m-$56.6Mn/m-$21.9Mn/m
Investing Cash Flow$0n/m$0n/m-$32Kn/m$659Kn/m$0n/m$0n/m-$264Kn/m-$90Kn/m
Financing Cash Flow-$2.1Mn/m-$99K-100.1%-$583K-315.1%$57.1Mn/m-$198Kn/m$93.8M-5.0%$271K-23.9%-$1.1Mn/m

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

ADCT Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

ADCT quarterly financial ratios
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Operating Margin-66.1%-132.0%-121.1%-77.7%-188.5%-234.3%-123.6%-191.8%
Net Margin-116.5%-86.1%-158.1%-27.8%-249.4%-300.7%-167.6%-181.7%
Return on Assets-9.9%+4.3pp-5.9%+11.7pp-11.3%+2.8pp-2.0%+7.6pp-14.1%-1.5pp-17.6%-7.8pp-14.2%+1.0pp-9.5%+14.4pp
Current Ratio3.05-1.6x3.03-1.9x4.09-0.4x4.37+0.7x4.63-0.3x4.93-1.2x4.46-0.1x3.62-1.4x
Asset Turnover0.080.0x0.070.0x0.070.0x0.070.0x0.060.0x0.060.0x0.080.0x0.050.0x
FCF Margin-128.4%-61.3%-142.6%-135.0%-180.4%-127.9%-245.7%-129.8%

Not reported in any period shown, so not listed: Gross Margin, Return on Equity, Debt-to-Equity, Liabilities-to-Equity.

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.

Note: Shareholder equity is negative (-$185.8M), which causes the debt-to-equity, liabilities-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.

Company Fiscal year Revenue Net income Net margin Market cap Health score
ADC Therapeutics SA ADCT FY2025 $81.4M -$142.6M N/A $180.0M 50/100
BioAge Labs, Inc. BIOA FY2025 $9.0M -$80.6M N/A $196.7M 56/100
SIGA Technologies, Inc. SIGA FY2025 $94.6M $23.3M 24.6% $172.5M 77/100
Canopy Growth Corporation CGC FY2026 $204.0M -$188.4M -92.4% $180.8M 34/100
Anika Therapeutics Inc ANIK FY2025 $112.8M -$10.9M -9.6% $177.2M 74/100
Lifecore Biomedical, Inc. LFCR FY2025 $128.9M -$38.7M -30.0% $242.2M 54/100

Frequently Asked Questions

ADC Therapeutics SA (ADCT) reported $81.4M in total revenue for fiscal year 2025. This represents a 14.9% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

ADC Therapeutics SA (ADCT) revenue grew by 14.9% year-over-year, from $70.8M to $81.4M in fiscal year 2025.

No, ADC Therapeutics SA (ADCT) reported a net loss of $81.2M over the trailing 12 months to September 30, 2026. In fiscal year 2025 it reported a net loss of $142.6M.

ADC Therapeutics SA (ADCT) reported diluted earnings per share of -$1.12 for fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

ADC Therapeutics SA (ADCT) had EBITDA of -$120.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

ADC Therapeutics SA (ADCT) had a gross margin of 92.9% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

ADC Therapeutics SA (ADCT) recorded an outflow of $141.4M in free cash flow during fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

ADC Therapeutics SA (ADCT) recorded an outflow of $141.2M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

ADC Therapeutics SA (ADCT) had $323.1M in total assets as of fiscal year 2025, including both current and long-term assets.

ADC Therapeutics SA (ADCT) invested $264K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

ADC Therapeutics SA (ADCT) invested $104.0M in research and development during fiscal year 2025.

ADC Therapeutics SA (ADCT) had 127M shares outstanding as of fiscal year 2025.

ADC Therapeutics SA (ADCT) had a current ratio of 4.37 as of fiscal year 2025, which is generally considered healthy.

ADC Therapeutics SA (ADCT) had a return on assets of -44.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

ADC Therapeutics SA (ADCT) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to September 30, 2026). The market capitalization is $180.0M as of Nov 20, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

ADC Therapeutics SA (ADCT) trades at 2.1x sales, its market capitalization divided by $84.9M revenue, trailing 12 months to September 30, 2026. The market capitalization is $180.0M as of Nov 20, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

At the end of fiscal year 2025, ADC Therapeutics SA (ADCT) held $261.3M in cash, cash equivalents and investments, and reported an operating cash outflow of $141.2M over that year. Dividing the one by the other, the reported balance equals about 22 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

ADC Therapeutics SA (ADCT) has negative shareholder equity of -$185.8M as of fiscal year 2025, so no debt-to-equity or liabilities-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

ADC Therapeutics SA (ADCT) has an Altman Z-Score of -6.99, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

ADC Therapeutics SA (ADCT) has a Piotroski F-Score of 5 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

ADC Therapeutics SA (ADCT) reported a net loss of $142.6M while operations used $141.2M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

ADC Therapeutics SA (ADCT) reported an operating loss of $121.5M against $16.3M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

ADC Therapeutics SA (ADCT) scores 50 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is the average of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.

Back to top